Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Contemp Clin Trials ; 118: 106794, 2022 07.
Article in English | MEDLINE | ID: covidwho-1850776

ABSTRACT

BACKGROUND: Practice-level quality improvement initiatives using rapidly advancing technology offers a multidimensional approach to reduce cardiovascular disease burden. For the "QUality improvement in primary care to prevent hospitalisations and improve Effectiveness and efficiency of care for people Living with heart disease" (QUEL) cluster randomised controlled trial, a 12-month quality improvement intervention was designed for primary care practices to use data and implement progressive changes using "Plan, Do, Study, Act" cycles within their practices with training in a series of interactive workshops. This protocol aims to describe the systematic methods to conduct a process evaluation of the data-driven intervention within the QUEL study. METHODS: A mixed-method approach will be used to conduct the evaluation. Quantitative data collected throughout the intervention period, via surveys and intervention materials, will be used to (1) identify the key elements of the intervention and how, for whom and in what context it was effective; (2) determine if the intervention is delivered as intended; and (3) describe practice engagement, commitment and capacity associated with various intervention components. Qualitative data, collected via semi-structured interviews and open-ended questions, will be used to gather in-depth understanding of the (1) satisfaction, utility, barriers and enablers; (2) acceptability, uptake and feasibility, and (3) effect of the COVID-19 pandemic on the implementation of the intervention. CONCLUSION: Findings from the evaluation will provide new knowledge on the implementation of a complex, multi-component intervention at practice-level using their own electronic patient data to enhance secondary prevention of cardiovascular disease. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry (ANZCTR) number ACTRN12619001790134.


Subject(s)
COVID-19 , Cardiovascular Diseases , Coronary Disease , Australia , COVID-19/prevention & control , Cardiovascular Diseases/prevention & control , Coronary Disease/prevention & control , Hospitalization , Humans , Pandemics , Quality Improvement , Randomized Controlled Trials as Topic
2.
Curr Opin Lipidol ; 32(3): 167-174, 2021 06 01.
Article in English | MEDLINE | ID: covidwho-1189521

ABSTRACT

PURPOSE OF REVIEW: The purpose of this review is to outline the relationship between cardiovascular disease (CVD) and depression, both as a cause of and a result of CVD. RECENT FINDINGS: The prevalence of depression seems to be increasing in the general population.It is likely that depression will be even more of a problem for CVD patients in the post-COVID-19 pandemic era.New studies confirm the independent association of depression with later incident CVD, although perhaps not as strong as suggested by some previous studies.Depression seems to be becoming even more prevalent in CVD patients, with new data for stroke and peripheral arterial disease patients.Cardiologists rarely screen for depression and most do not believe that they have a responsibility for detecting or treating depression.There are new data suggesting that patients who are more in control of their lives have better outcomes and that change is possible. SUMMARY: Depression is preventable and treatable. It is imperative to detect and manage depression in CVD patients. Additional research is required to see whether or not comprehensive patient screening for depression translates into both better quality of life and improved clinical outcomes.


Subject(s)
Cardiovascular Diseases/complications , Depression/complications , Cardiovascular Diseases/metabolism , Cardiovascular Diseases/physiopathology , Depression/metabolism , Depression/physiopathology , Disabled Persons , Humans , Lipid Metabolism , Prevalence
3.
Heart Lung Circ ; 29(7): 960-963, 2020 Jul.
Article in English | MEDLINE | ID: covidwho-607676

ABSTRACT

BACKGROUND: The coronavirus disease (COVID-19) pandemic has produced substantial health challenges from the perspective of both its direct health complications and the disruption to delivery of standard care for individuals with a range of acute and chronic health issues. In parallel, the widespread application of social isolation initiatives in most countries raises the potential for significant mental health consequences and psychosocial impacts. This has major implications for cardiovascular health care professionals and the management of their patients. CHALLENGES: The COVID-19 pandemic and associated physical isolation practices are likely to result in a range of mental health and psychosocial challenges. In addition to an increasing incidence of anxiety, depression, suicidal ideation and post-traumatic stress, the pandemic may also witness an increase in substance abuse, domestic violence and relationship discord. The consequences of these complications will be further magnified, when considering their potential effect on cardiovascular disease and its management. PURPOSE: This commentary aims to summarise some of the potential mental health and psychosocial challenges that may arise in the setting of the COVID-19 pandemic.


Subject(s)
Cardiovascular Diseases , Coronavirus Infections/psychology , Mental Health , Pneumonia, Viral/psychology , Psychology , Betacoronavirus , COVID-19 , Cardiovascular Diseases/psychology , Cardiovascular Diseases/therapy , Coronavirus Infections/epidemiology , Coronavirus Infections/prevention & control , Humans , Pandemics/prevention & control , Pneumonia, Viral/epidemiology , Pneumonia, Viral/prevention & control , SARS-CoV-2
4.
Heart Lung Circ ; 29(7): e99-e104, 2020 Jul.
Article in English | MEDLINE | ID: covidwho-155330

ABSTRACT

BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has introduced a major disruption to the delivery of routine health care across the world. This provides challenges for the use of secondary prevention measures in patients with established atherosclerotic cardiovascular disease (CVD). The aim of this Position Statement is to review the implications for effective delivery of secondary prevention strategies during the COVID-19 pandemic. CHALLENGES: The COVID-19 pandemic has introduced limitations for many patients to access standard health services such as visits to health care professionals, medications, imaging and blood tests as well as attendance at cardiac rehabilitation. In addition, the pandemic is having an impact on lifestyle habits and mental health. Taken together, this has the potential to adversely impact the ability of practitioners and patients to adhere to treatment guidelines for the prevention of recurrent cardiovascular events. RECOMMENDATIONS: Every effort should be made to deliver safe, ongoing access to health care professionals and the use of evidenced based therapies in individuals with CVD. An increase in use of a range of electronic health platforms has the potential to transform secondary prevention. Integrating research programs that evaluate the utility of these approaches may provide important insights into how to develop more optimal approaches to secondary prevention beyond the pandemic.


Subject(s)
Cardiac Rehabilitation , Cardiology , Cardiovascular Diseases , Coronavirus Infections , Infection Control/organization & administration , Pandemics , Pneumonia, Viral , Secondary Prevention , Australia/epidemiology , Betacoronavirus , COVID-19 , Cardiac Rehabilitation/methods , Cardiac Rehabilitation/trends , Cardiology/methods , Cardiology/organization & administration , Cardiology/trends , Cardiovascular Diseases/complications , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/prevention & control , Consensus , Coronavirus Infections/epidemiology , Coronavirus Infections/prevention & control , Delivery of Health Care/organization & administration , Humans , New Zealand/epidemiology , Pandemics/prevention & control , Pneumonia, Viral/epidemiology , Pneumonia, Viral/prevention & control , SARS-CoV-2 , Secondary Prevention/methods , Secondary Prevention/organization & administration , Societies, Medical
SELECTION OF CITATIONS
SEARCH DETAIL